Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Role of Dipyrone in the High On-Treatment Platelet Reactivity amongst Acetylsalicylic Acid-Treated Patients Undergoing Peripheral Artery Revascularisation

J. Hartinger, R. Novotny, J. Bilkova, T. Kvasnicka, P. Mitas, M. Sima, J. Hlubocky, J. Kvasnicka, O. Slanar, J. Lindner,

. 2018 ; 27 (4) : 356-361. [pub] 20180513

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012672

OBJECTIVE: To evaluate the effects of dipyrone on sensitivity to aspirin (acetylsalicylic acid [ASA]) in patients who underwent peripheral artery vascular reconstruction. SUBJECTS AND METHODS: Impedance aggregometry and light transmission aggregometry were used to determine the effects of dipyrone on ASA treatment in 21 patients. Blood samples were drawn in a 7-day period after the surgery. The cut-off value for high on-treatment platelet reactivity (HTPR) was set at < 65% of aggregation inhibition for impedance aggregometry. For light transmission aggregometry the cut-off value for arachidonic acid-induced aggregation was set at > 20% of aggregating platelets, and the cut-off value for epinephrine-induced aggregation was > 44% of aggregating platelets. The cut-off value for each method was derived from a large number of patients treated with a daily dose of 100 mg of ASA. RESULTS: We found HTPR in 14 (67%) of the 21 patients. None had primary resistance to ASA, i.e., after the addition of ASA in vitro all samples showed antiplatelet efficacy. Regression analysis showed a possible correlation between lower efficacy of ASA treatment and higher daily doses of dipyrone (p = 0.005 for impedance aggregometry, p = 0.04 for light transmission aggregometry), higher platelet count (p = 0.005 for impedance aggregometry), and shorter time from surgery (p = 0.03 for impedance aggregometry). CONCLUSION: HTPR occurs in 67% of ASA-treated patients after lower limb vascular surgery. The occurrence of HTPR correlates with the daily dose of dipyrone. Therefore, dipyrone should not be used as a postoperative analgesic in ASA-treated patients after peripheral artery revascularisation due to its influence on the effectiveness of ASA.

000      
00000naa a2200000 a 4500
001      
bmc19012672
003      
CZ-PrNML
005      
20240522100231.0
007      
ta
008      
190405s2018 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000489970 $2 doi
035    __
$a (PubMed)29754149
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Hartinger, Jan $u Department of Clinical Pharmacology and Pharmacy, Institute of Pharmacology, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. $7 xx0224709
245    10
$a Role of Dipyrone in the High On-Treatment Platelet Reactivity amongst Acetylsalicylic Acid-Treated Patients Undergoing Peripheral Artery Revascularisation / $c J. Hartinger, R. Novotny, J. Bilkova, T. Kvasnicka, P. Mitas, M. Sima, J. Hlubocky, J. Kvasnicka, O. Slanar, J. Lindner,
520    9_
$a OBJECTIVE: To evaluate the effects of dipyrone on sensitivity to aspirin (acetylsalicylic acid [ASA]) in patients who underwent peripheral artery vascular reconstruction. SUBJECTS AND METHODS: Impedance aggregometry and light transmission aggregometry were used to determine the effects of dipyrone on ASA treatment in 21 patients. Blood samples were drawn in a 7-day period after the surgery. The cut-off value for high on-treatment platelet reactivity (HTPR) was set at < 65% of aggregation inhibition for impedance aggregometry. For light transmission aggregometry the cut-off value for arachidonic acid-induced aggregation was set at > 20% of aggregating platelets, and the cut-off value for epinephrine-induced aggregation was > 44% of aggregating platelets. The cut-off value for each method was derived from a large number of patients treated with a daily dose of 100 mg of ASA. RESULTS: We found HTPR in 14 (67%) of the 21 patients. None had primary resistance to ASA, i.e., after the addition of ASA in vitro all samples showed antiplatelet efficacy. Regression analysis showed a possible correlation between lower efficacy of ASA treatment and higher daily doses of dipyrone (p = 0.005 for impedance aggregometry, p = 0.04 for light transmission aggregometry), higher platelet count (p = 0.005 for impedance aggregometry), and shorter time from surgery (p = 0.03 for impedance aggregometry). CONCLUSION: HTPR occurs in 67% of ASA-treated patients after lower limb vascular surgery. The occurrence of HTPR correlates with the daily dose of dipyrone. Therefore, dipyrone should not be used as a postoperative analgesic in ASA-treated patients after peripheral artery revascularisation due to its influence on the effectiveness of ASA.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antiflogistika nesteroidní $x farmakologie $7 D000894
650    _2
$a Aspirin $x škodlivé účinky $7 D001241
650    _2
$a trombocyty $x účinky léků $7 D001792
650    _2
$a periferní katetrizace $7 D002406
650    _2
$a nemoci koronárních tepen $x krev $7 D003324
650    _2
$a metamizol $x farmakologie $7 D004177
650    _2
$a lékové interakce $7 D004347
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a koronární angioplastika $7 D062645
650    _2
$a agregace trombocytů $x účinky léků $7 D010974
650    _2
$a inhibitory agregace trombocytů $x farmakologie $7 D010975
650    _2
$a regresní analýza $7 D012044
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Novotny, Robert $u Transplant Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Bilkova, Jana $u Thrombotic Centre, General University Hospital, Prague, Czech Republic.
700    1_
$a Kvasnicka, Tomas $u Thrombotic Centre, General University Hospital, Prague, Czech Republic.
700    1_
$a Mitas, Petr $u 2nd Department of Cardiovascular Surgery, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Sima, Martin $u Department of Clinical Pharmacology and Pharmacy, Institute of Pharmacology, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Hlubocky, Jaroslav $u 2nd Department of Cardiovascular Surgery, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Kvasnicka, Jan $u Thrombotic Centre, General University Hospital, Prague, Czech Republic.
700    1_
$a Slanar, Ondrej $u Department of Clinical Pharmacology and Pharmacy, Institute of Pharmacology, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Lindner, Jaroslav $u 2nd Department of Cardiovascular Surgery, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
773    0_
$w MED00190076 $t Medical principles and practice $x 1423-0151 $g Roč. 27, č. 4 (2018), s. 356-361
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29754149 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20240522100226 $b ABA008
999    __
$a ok $b bmc $g 1391982 $s 1050977
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 27 $c 4 $d 356-361 $e 20180513 $i 1423-0151 $m Medical principles and practice $n Med Princ Pract $x MED00190076
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Možnosti archivace